Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 481 to 482 of 482 entries
Sorted by: Best Match Show Resources per page
Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions.

Cell reports. Medicine

Filbin MR, Mehta A, Schneider AM, Kays KR, Guess JR, Gentili M, Fenyves BG, Charland NC, Gonye ALK, Gushterova I, Khanna HK, LaSalle TJ, Lavin-Parsons KM, Lilley BM, Lodenstein CL, Manakongtreecheep K, Margolin JD, McKaig BN, Rojas-Lopez M, Russo BC, Sharma N, Tantivit J, Thomas MF, Gerszten RE, Heimberg GS, Hoover PJ, Lieb DJ, Lin B, Ngo D, Pelka K, Reyes M, Smillie CS, Waghray A, Wood TE, Zajac AS, Jennings LL, Grundberg I, Bhattacharyya RP, Parry BA, Villani AC, Sade-Feldman M, Hacohen N, Goldberg MB.
PMID: 33969320
Cell Rep Med. 2021 May 18;2(5):100287. doi: 10.1016/j.xcrm.2021.100287. Epub 2021 May 03.

Mechanisms underlying severe coronavirus disease 2019 (COVID-19) disease remain poorly understood. We analyze several thousand plasma proteins longitudinally in 306 COVID-19 patients and 78 symptomatic controls, uncovering immune and non-immune proteins linked to COVID-19. Deconvolution of our plasma proteome...

Cite
Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021;2(5):100287doi: 10.1016/j.xcrm.2021.100287.
Filbin, M. R., Mehta, A., Schneider, A. M., Kays, K. R., Guess, J. R., Gentili, M., Fenyves, B. G., Charland, N. C., Gonye, A. L. K., Gushterova, I., Khanna, H. K., LaSalle, T. J., Lavin-Parsons, K. M., Lilley, B. M., Lodenstein, C. L., Manakongtreecheep, K., Margolin, J. D., McKaig, B. N., Rojas-Lopez, M., Russo, B. C., Sharma, N., Tantivit, J., Thomas, M. F., Gerszten, R. E., Heimberg, G. S., Hoover, P. J., Lieb, D. J., Lin, B., Ngo, D., Pelka, K., Reyes, M., Smillie, C. S., Waghray, A., Wood, T. E., Zajac, A. S., Jennings, L. L., Grundberg, I., Bhattacharyya, R. P., Parry, B. A., Villani, A. C., Sade-Feldman, M., Hacohen, N., & Goldberg, M. B. (2021). Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell reports. Medicine, 2(5), 100287. https://doi.org/10.1016/j.xcrm.2021.100287
Filbin, Michael R, et al. "Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions." Cell reports. Medicine vol. 2,5 (2021): 100287. doi: https://doi.org/10.1016/j.xcrm.2021.100287
Filbin MR, Mehta A, Schneider AM, Kays KR, Guess JR, Gentili M, Fenyves BG, Charland NC, Gonye ALK, Gushterova I, Khanna HK, LaSalle TJ, Lavin-Parsons KM, Lilley BM, Lodenstein CL, Manakongtreecheep K, Margolin JD, McKaig BN, Rojas-Lopez M, Russo BC, Sharma N, Tantivit J, Thomas MF, Gerszten RE, Heimberg GS, Hoover PJ, Lieb DJ, Lin B, Ngo D, Pelka K, Reyes M, Smillie CS, Waghray A, Wood TE, Zajac AS, Jennings LL, Grundberg I, Bhattacharyya RP, Parry BA, Villani AC, Sade-Feldman M, Hacohen N, Goldberg MB. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021 May 18;2(5):100287. doi: 10.1016/j.xcrm.2021.100287. Epub 2021 May 03. PMID: 33969320; PMCID: PMC8091031.
Copy Download .nbib Format: NLM
Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials.

Pain and therapy

Hammer GB, Khanna AK, Michalsky C, Wase L, Demitrack MA, Little R, Fossler MJ, Ayad S.
PMID: 34351590
Pain Ther. 2021 Dec;10(2):1343-1353. doi: 10.1007/s40122-021-00299-0. Epub 2021 Aug 05.

INTRODUCTION: In the management of postoperative acute moderate-to-severe pain, opioids remain an important component. However, conventional opioids have a narrow therapeutic index and are associated with dose-limiting opioid-related adverse events (ORAEs) that can result in worse patient outcomes. Oliceridine,...

Cite
Hammer GB, Khanna AK, Michalsky C, et al. Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. Pain Ther. 2021;10(2):1343-1353doi: 10.1007/s40122-021-00299-0.
Hammer, G. B., Khanna, A. K., Michalsky, C., Wase, L., Demitrack, M. A., Little, R., Fossler, M. J., & Ayad, S. (2021). Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. Pain and therapy, 10(2), 1343-1353. https://doi.org/10.1007/s40122-021-00299-0
Hammer, Gregory B, et al. "Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials." Pain and therapy vol. 10,2 (2021): 1343-1353. doi: https://doi.org/10.1007/s40122-021-00299-0
Hammer GB, Khanna AK, Michalsky C, Wase L, Demitrack MA, Little R, Fossler MJ, Ayad S. Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. Pain Ther. 2021 Dec;10(2):1343-1353. doi: 10.1007/s40122-021-00299-0. Epub 2021 Aug 05. PMID: 34351590; PMCID: PMC8586048.
Copy Download .nbib Format: NLM
Showing 481 to 482 of 482 entries